Animal & Plant Derived Vaccines

It has been about 30 years since the first plant engineering technology was established. Although the concept of plant-based pharmaceuticals or vaccines motivates us to develop practicable commercial products using plant engineering, there are some difficulties in reaching the final goal: to manufacture an approved product. At present, the only plant-made vaccine approved by the United States Department of Agriculture is a Newcastle disease vaccine for poultry that is produced in suspension-cultured tobacco cells. The progress toward commercialization of plant-based vaccines takes much effort and time, but several candidate vaccines for use in humans and animals are in clinical trials. This review discusses plant engineering technologies and regulations relevant to the development of plant-based vaccines and provides an overview of human and animal vaccines currently under clinical trials.

  • Bovine and porcine products
  • Chicken embryos and embryonated eggs
  • Plants as bioreactors
  • Chloroplast-derived protozoan antigens
  • Chloroplast-derived autoantigens

Related Conference of Animal & Plant Derived Vaccines

July 27-28, 2018

31st Annual Congress on Vaccines, Clinical Trials & B2B

Vancouver, Canada
September 19-20, 2018

International Congress on Vaccines & Immunology

Amsterdam, Netherlands
October 22-23, 2018

30th World Congress on Vaccines and Immunization

Osaka, Japan
March 18-19, 2019

33rdAnnual Vaccines & Vaccination Congress

New York, USA

Animal & Plant Derived Vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in